M&A - GILEAD SCIENCES, INC.

Form Type: SCHEDULE 13G/A

Filing Date: 2025-03-20

Corporate Action: Merger

Type: Update

Accession Number: 000112329225000148

Filing Summary: On March 18, 2025, a merger took place between Gilead Sciences, Inc. and Kalaris Therapeutics, Inc. The transaction was governed by the Agreement and Plan of Merger dated November 7, 2024. Following the merger's Effective Time, Gilead Sciences changed its name to Kalaris Therapeutics, Inc., and the Common Stock transitioned from trading on The Nasdaq Capital Market under the ticker symbol 'ALVR' to The Nasdaq Global Market under the new ticker symbol 'KLRS' on March 19, 2025. The number of shares outstanding post-merger was recorded at 18,702,413, corresponding to a 3.9% ownership stake for Gilead post-transaction. This document provides evidence of compliance under Rule 13d-1(c), affirming that the securities in question were not acquired for the purpose of influencing control of the issuer.